Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the potential therapeutic value of early passive polyclonal immunotherapy using high-titer convalescent plasma (CCP). Human polyclonal hyperimmune immunoglobulin (HIG) has several advantages over CCP. Unlike CCP, HIG can provide standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Burnouf, Thierry, Gathof, Birgit, Bloch, Evan M., Bazin, Renée, de Angelis, Vincenzo, Patidar, Gopal Kumar, Rastvorceva, Rada M. Grubovic, Oreh, Adaeze, Goel, Ruchika, Rahimi-Levene, Naomi, Hindawi, Salwa, Al-Riyami, Arwa Z., So-Osman, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183240/
https://www.ncbi.nlm.nih.gov/pubmed/35879213
http://dx.doi.org/10.1016/j.tmrv.2022.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183240/
https://www.ncbi.nlm.nih.gov/pubmed/35879213
http://dx.doi.org/10.1016/j.tmrv.2022.06.001

Ejemplares similares